Sidney A. Scudder, M.D.
Professor
To see if Sidney A. Scudder is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Physician Referrals
Clinical Interests
Sidney A. Scudder directs the Infusion Center. His interests lie in the treatment of gynecologic malignancies, especially ovarian and cervical cancer, and in concurrent chemotherapy and radiation therapy for these diseases. He participates in basic and translational research with an emphasis on pharmacology and new drug development.
Division
Hematology and Oncology
Center/Program Affiliation
Undergraduate School
B.S., University of Florida, Gainesville FL 1980
Medical School
M.D., University of Florida College of Medicine, Gainesville FL 1980
Internship
Internal Medicine, Barnes Hospital, St. Louis MO 1980-1983
Residency
Internal Medicine, Barnes Hospital, St. Louis MO 1980-1983
Fellowship
Medical Oncology Clinical, Stanford University Hospital, Stanford CA 1983-1985
Peer voted Top Doctor in for Cancer in US, 2011, 2012, 2013, 2014
American Society of Clinical Oncology Travel Award, 1987
Walter Oppelt Award in Pharmacology and Therapeutics, 1980
Paula Ellis Scholarship, 1980
Olive Levine, Damon Runyon and Walter Winchell Scholarship, 1978
For a comprehensive list of Dr. Scudder's publications, please click here.
Ho HL, Jiang Y, Chiang CL, Karwowska S, Yerram R, Sharma K, Scudder S, Chiu CH, Tsai CM, Palma JF, Sharma A, Chou TY. Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PLoS One. 2022 Apr 28;17(4):e0267362. doi:10.1371/journal.pone.0267362. PMID:35482671.
O'Donnell P, May T, DeMartin K, Ferguson J, Halait H, Wei W, Yu K, Scudder S. Performance Characteristics of a Real-Time Polymerase Chain Reaction Assay for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Plasma Samples of Non-Small Cell Lung Cancer (NSCLC) Patients. Mol Diagn Ther. 2020 Aug;24(4):451-460. doi:10.1007/s40291-020-00458-7. PMID:32406048.
Kern I, Cufer T, Rot M, Scudder S et al. Dynamic Changes of EGFR Activating Mutations as an Early Predictor of Progression in Non–Small Cell Lung Cancer Patients Treated with EGFR Tyrosine Kinase Inhibitors. J Mol Biomark Diagn. 2020;11:3. doi:10.37421/jmbd.2020.11.425.
Yu K, Karwowska S, Sharma A, Liesenfeld O, Scudder SA. Polymerase Chain Reaction. Jorgensen JT (ed). Companion and Complementary Diagnostics, Medical and Scientific Affairs, Roche Molecular Diagnostics, Pleasanton CA. 2019. doi:10.1016/B978-0-12-813539-6.00006-7.
Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, Wang J, Zhou C, Appius A, Button P, Hooper G, Palma JF, Schulze K, Scudder S, Shames DS, Yin AY, Zhang G, Mok T; ENSURE FASTACT-2 and ASPIRATION Investigators. Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies. Lung Cancer. 2018 Dec;126:1-8. doi:10.1016/j.lungcan.2018.10.004. Epub 2018 Oct 9. PMID:30527172.
Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC. Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. J Mol Diagn. 2018 Jul;20(4):483-494. doi:10.1016/j.jmoldx.2018.03.006. Epub 2018 Apr 26. PMID:29704571.
Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O. The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer. J Pers Med. 2017 Jun 28;7(3):5. doi:10.3390/jpm7030005. PMID:28657610.
Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct;135(1):25-33. doi:10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11. PMID:25019569.
Rock CL, Natarajan L, Pu M, Thomson CA, Flatt SW, Caan BJ, Gold EB, Al-Delaimy WK, Newman VA, Hajek RA, Stefanick ML, Pierce JP; Women's Healthy Eating and Living Study Group. Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the Women's Healthy Eating and Living Study. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):486-94. doi:10.1158/1055-9965.EPI-08-0809. Epub 2009 Feb 3. PMID:19190138.